Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Climb Bio, Inc.

Get SEC filing alerts via email and in your feed for Climb Bio, Inc.

CLYM

Climb Bio, Inc.

About Climb Bio, Inc.

Climb Bio, Inc. is a biotechnology company focused on developing innovative therapeutics for immune-mediated diseases. Its pipeline includes monoclonal antibodies targeting B-cell pathways, such as CD19 and APRIL, to treat conditions like membranous nephropathy, ITP, SLE, and IgA nephropathy. The company leverages licensing, strategic acquisitions, and clinical-stage programs to address high unmet medical needs with targeted, potentially disease-modifying therapies.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Climb Bio, Inc.

1
1
Climb Bio, Inc. Climb Bio Reports Q1 2026 Financial Results with Improved Net Loss of $13.7 Million

Via official filing (AI summary) | 30 days ago | 0 comments

2
1
Climb Bio, Inc. Climb Bio Reports $59.9 Million Net Loss for 2025, Advances Clinical Trials for Budoprutug

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Climb Bio, Inc. Climb Bio Reports $12.9 Million Net Loss in Q3 2025, Highlights R&D Expenses and Clinical Trials

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Climb Bio, Inc. Climb Bio Reports $8.7 Million Net Loss, Advances Clinical Trials for Budoprutug

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Climb Bio, Inc. Climb Bio Reports $20.8 Million Net Loss and Increased R&D Expenses in Latest 10-Q Filing

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Climb Bio, Inc. Climb Bio Reports $73.9 Million Net Loss for 2024, Highlights Acquisition and R&D Developments

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Climb Bio, Inc. Climb Bio Reports Significant Financial Developments, Net Loss Increases 124.2% in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments